Form 4: RAPT Director Sells Shares Post-GSK Merger

RAPT Therapeutics Director Scott Braunstein reported the disposition of common stock and stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.

Summary

• Scott Braunstein, a Director of RAPT Therapeutics, Inc., reported changes in his beneficial ownership following the company's acquisition.
• The transactions occurred on March 3, 2026, coinciding with the completion of the merger between RAPT Therapeutics and GlaxoSmithKline LLC.
• GlaxoSmithKline, through its subsidiary Redrose Acquisition Co., acquired all outstanding shares of RAPT Therapeutics common stock for $58.00 per share in cash.
• Braunstein disposed of 4,956 restricted stock units (RSUs) and 25,000 director stock options.
• The RSUs were cancelled and converted into a cash payment based on the $58.00 offer price.
• The stock options, with an exercise price of $7.44, were accelerated, fully vested, and then cancelled, converting into a cash payment based on the difference between the $58.00 offer price and the exercise price.
• Following these transactions, Braunstein beneficially owns 0 shares of RAPT Therapeutics common stock and 0 derivative securities.
• Braunstein is no longer subject to Section 16 reporting obligations for RAPT Therapeutics.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for RAPT shareholders, as the acquisition provided a clear, premium cash exit. The filing itself is a routine post-merger report, reflecting the successful completion of the transaction.

Positives

• The merger with GlaxoSmithKline at $58.00 per share provided a clear exit strategy and liquidity for shareholders and option holders.
• Stock options were accelerated and fully vested, allowing holders to realize value from their equity awards.

Negatives

• RAPT Therapeutics ceased to be an independent publicly traded entity, becoming an indirect wholly owned subsidiary of GSK.
• Existing RAPT shareholders no longer participate in the company's future growth as an independent entity.

Risks

• No new risks for RAPT Therapeutics as an independent entity are identified in this post-merger transaction report, as the company has been acquired.

Future Outlook

The filing primarily reports a completed merger and insider transactions, thus it does not provide forward-looking statements or guidance for RAPT Therapeutics as an independent entity. RAPT Therapeutics is now an indirect wholly owned subsidiary of GlaxoSmithKline LLC.

Industry Context

StockSavvy.ai notes that the acquisition of RAPT Therapeutics by GlaxoSmithKline reflects a broader trend in the pharmaceutical and biotechnology sectors where larger established players acquire smaller, innovative companies to bolster their pipelines and intellectual property. This particular acquisition likely targeted RAPT's therapeutic candidates, integrating them into GSK's R&D portfolio.

Comparison to Industry Standards

• StockSavvy.ai observes that the $58.00 per share offer price represents a significant premium over RAPT's pre-announcement trading levels, which is common in strategic acquisitions within the biotech sector.
• Similar acquisitions like Pfizer's acquisition of Seagen for $43 billion (approximately $229 per share) or Merck's acquisition of Prometheus Biosciences for $10.8 billion (approximately $200 per share) also demonstrated substantial premiums, reflecting the high value placed on promising drug candidates and technology platforms.
• The cash-only nature of the deal provides immediate and certain value to RAPT shareholders, aligning with typical acquisition structures for smaller biotech firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $58.00 per share in cash, providing liquidity and a premium for their investment. No longer hold shares in an independent RAPT Therapeutics.
• Employees: RAPT Therapeutics continues as an operating entity under GSK, but the long-term impact on employment structure and benefits is not detailed in this filing. Equity holders (including employees with options/RSUs) received cash payouts.
• Customers/Suppliers: No direct impact mentioned in this filing. Operations likely continue under GSK's ownership.
• Creditors: No direct impact mentioned in this filing.

Key Dates

Keywords

RAPT Therapeutics, GSK, GlaxoSmithKline, Merger, Acquisition, Form 4, Insider Trading, Stock Options, RSUs, Tender Offer, Biotechnology, Pharmaceuticals